Clodagh O'Shea Johnson, L Bagus, B Choi, S Nicholas, C Shen, A Boyle, L Pandey, K Soria, C Kunich, J
...
Published in
Cancer Cell International
ONYX-015 is an adenovirus that lacks the E1B-55K gene product for p53 degradation. Thus, ONYX-015 was conceived as an oncolytic virus that would selectively replicate in p53-defective tumor cells. Here we show that loss of E1B-55K leads to the induction, but not the activation, of p53 in ONYX-015-infected primary cells. We use a novel adenovirus mu...
Ringshausen, I Clodagh O'Shea Finch, Aj Swigart, Lb Evan, Gi
Published in
Cancer Cell International
There is currently much interest in the idea of restoring p53 activity in tumor cells by inhibiting Hdm2/Mdm2. However, it has remained unclear whether this would also activate p53 in normal cells. Using a switchable endogenous p53 mouse model, which allows rapid and reversible toggling of p53 status between wild-type and null states, we show that ...
Clodagh O'Shea Soria, C Bagus, B Mccormick, F
Published in
Cancer Cell International
ONYX-015 is an E1B-55K-deleted adenovirus that has promising clinical activity as a cancer therapy. However, many tumor cells fail to support ONYX-015 oncolytic replication. E1B-55K functions include p53 degradation, RNA export, and host protein shutoff. Here, we show that resistant tumor cell lines fail to provide the RNA export functions of E1B-5...